Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 102

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 102
---
ised on the completion of such animal study and our review of
the results thereof. In case the study yields positive results, we will need to assess the industrial viability of the program, including
evaluating manufacturing options and obtaining price quotes from several viable biotechnology CDMOs. Based on this assessment, we will
be able to conclude on the development plan and define the corresponding regulatory strategy..

The LPLT-based immunization platform is expected to:

| - | Significantly                                                                         
 improve vaccines’ efficiency and be more durable than mRNA vaccines and, potentially, 
 provide longer-lasting protection                                                     |

| - | Provide                                                       
 broader cross-immunity to protect against new virus variants. |

| - | Expected                                                                                      
 to boost the immune system of people vaccinated with other vaccines as well as to effectively 
 stop the spread of the pandemic.                                                              |

Recent animal studies conducted by Prof. Barenholz
demonstrated that the new LPLT technology induced strong immune response and high levels of antibodies. The platform uses a recombinant
technology that is suggested to protect against transmission of a specific virus using 2 different protein sequences encapsulated in novel
lipid nanoparticles.

The platform is expected to efficiently interrupt
the transmission chain and stop the rapid and deadly spread, in cases of bird flu, Ebola and others. High mucosal immunity demonstrated
in animal experiments may be critical in fighting Coronavirus mutations and other deadly viruses.

LPLT technology may potentially have several advantages
over the current methods of protein delivery. Firstly, this drug-delivery technology is designed to protect the proteins from degradation
and clearance by the immune system or the liver, thus increasing their half-life and reducing the frequency and dose of administration.
Secondly, it can improve the biodistribution and accumulation of the proteins at the desired sites of action, such as inflamed tissues,
or infected cells, thus increasing their efficacy and reducing their side effects.

<div align='center'>63</div>

The Company is currently awaiting the completion
of a SARS-CoV-2 challenge study involving 114 ACE2-transgenic mice, previously committed to by Prof. Barenholz and expected to conclude
in the third quarter of 2025 to evaluate the short- and long-term protective efficacy of the LPLT vaccine. The results of this study
are critical to determining the commercial viability of continued investment in this program.

LPLT protein delivery technology is patent protected.

| Status  |     | Country |     | Application Date |     | Publication Number |